Should I buy or sell NeuroSense Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroSense Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NRSN shares. View NRSN analyst ratings or view top-rated stocks .

How have NRSN shares performed in 2023?

NeuroSense Therapeutics' stock was trading at $1.22 at the beginning of the year. Since then, NRSN stock has decreased by 42.2% and is now trading at $0.7046. View the best growth stocks for 2023 here .

Are investors shorting NeuroSense Therapeutics?

NeuroSense Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 234,000 shares, an increase of 89.3% from the October 31st total of 123,600 shares. Based on an average daily volume of 240,800 shares, the days-to-cover ratio is currently 1.0 days. Approximately 2.6% of the company's stock are sold short. View NeuroSense Therapeutics' Short Interest .

When is NeuroSense Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our NRSN earnings forecast .

When did NeuroSense Therapeutics IPO?

(NRSN) raised $13 million in an initial public offering (IPO) on Thursday, December 9th 2021. The company issued 2,000,000 shares at $6.00-$7.00 per share.

Who are NeuroSense Therapeutics' major shareholders?

NeuroSense Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (6.05%).

How do I buy shares of NeuroSense Therapeutics?

Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

NeuroSense Therapeutics Stock Price, News & Analysis (NASDAQ:NRSN)

$0.75

+0.03 (+3.61%)

(As of 02:32 PM ET)

Compare

Today's Range: $0.65
▼
$0.76
50-Day Range: $0.44
▼
$1.49
52-Week Range: $0.40
▼
$2.91

Volume: 703,028 shs
Average Volume: 617,946 shs
Market Capitalization: $8.22 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About NeuroSense Therapeutics Stock (NASDAQ:NRSN)

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

NRSN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NRSN Stock News Headlines

December 6, 2023 | finance.yahoo.com

We're A Little Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate

December 5, 2023 | marketwatch.com

NeuroSense Therapeutics Sees Positive Safety Data in Phase 2 Trial for ALS Treatment, Shares Fall

December 7, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

December 5, 2023 | markets.businessinsider.com

NeuroSense Says Phase 2b ALS Trial Meets Primary And Secondary Endpoints

December 5, 2023 | msn.com

NeuroSense ALS candidate meets key study goals

December 5, 2023 | finance.yahoo.com

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

December 4, 2023 | finance.yahoo.com

NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023

November 28, 2023 | msn.com

NeuroSense Therapeutics GAAP EPS of -$0.67

December 7, 2023 | Edge On The Street (Ad)

Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?

A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.

November 28, 2023 | markets.businessinsider.com

NeuroSense Therapeutics 9-Month Loss Narrows

November 28, 2023 | finance.yahoo.com

NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update

November 13, 2023 | markets.businessinsider.com

NeuroSense Therapeutics Concludes Successful Type D Meeting With FDA For ALS Treatment

November 13, 2023 | finance.yahoo.com

NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness

November 6, 2023 | finance.yahoo.com

NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023

November 1, 2023 | finance.yahoo.com

NeuroSense Therapeutics to Participate in BIO-Europe Fall

October 19, 2023 | finance.yahoo.com

Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics’ Lead Drug Candidate, PrimeC

October 17, 2023 | finance.yahoo.com

NeuroSense CEO Provides Q3 2023 Update

October 4, 2023 | finance.yahoo.com

NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model

September 25, 2023 | barrons.com

NeuroSense Therapeutics Ltd. Wt

September 20, 2023 | finance.yahoo.com

European Medicines Agency Grants NeuroSense SME Status

September 19, 2023 | finance.yahoo.com

NeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC

September 14, 2023 | finance.yahoo.com

NeuroSense to Participate in Upcoming ALS Conferences: PACTALS in Malaysia and NEALS in the U.S.

September 6, 2023 | finance.yahoo.com

NeuroSense to Host Investor Webinar on September 12, 2023

August 16, 2023 | finance.yahoo.com

NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update

July 17, 2023 | finance.yahoo.com

NeuroSense to Host Investor Event in Cambridge, Massachusetts on July 24, 2023

July 6, 2023 | finance.yahoo.com

NeuroSense CEO Provides Q2 2023 Update

June 22, 2023 | finance.yahoo.com

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

See More Headlines

Receive NRSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 12/07/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NRSN
CUSIP: N/A
CIK: 1875091
Web: www.neurosense-tx.com
Phone: 972-9799-6183
Fax: N/A
Employees: 14
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.94)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-12,340,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -678.59%
Return on Assets: -174.61%

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 1.82
Quick Ratio: 2.80

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.51 per share
Price / Book: 1.42

Miscellaneous

Outstanding Shares: 10,940,000
Free Float: N/A
Market Cap: $7.93 million
Optionable: Not Optionable
Beta: 1.65

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Alon Ben-Noon (Age 44)
Co-Founder, CEO & Director
Comp: $619k
Mr. Or Eisenberg (Age 42)
Chief Financial Officer
Comp: $378k
Dr. Ferenc Tracik M.D. (Age 59)
Chief Medical Officer
Comp: $513k
Ms. Hagit Binder (Age 45)
Chief Operation Officer
Dr. Niva Russek-Blum Ph.D. (Age 44)
Chief Technology Officer
Ms. Yael Barak (Age 53)
VP of Quality & Compliance
Ms. Keren Pushett
Head of HR
Mr. Eidan Loushi
C.R.A.

Key Competitors

View All Competitors

Institutional Ownership

Armistice Capital LLC
Sold 604,000 shares on 11/15/2023
Ownership: 6.051%

View All Institutional Transactions

NRSN Stock Analysis - Frequently Asked Questions

Should I buy or sell NeuroSense Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroSense Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NRSN shares.
View NRSN analyst ratings or view top-rated stocks.
How have NRSN shares performed in 2023?: NeuroSense Therapeutics' stock was trading at $1.22 at the beginning of the year. Since then, NRSN stock has decreased by 42.2% and is now trading at $0.7046.
View the best growth stocks for 2023 here.
Are investors shorting NeuroSense Therapeutics?: NeuroSense Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 234,000 shares, an increase of 89.3% from the October 31st total of 123,600 shares. Based on an average daily volume of 240,800 shares, the days-to-cover ratio is currently 1.0 days. Approximately 2.6% of the company's stock are sold short.
View NeuroSense Therapeutics' Short Interest.
When is NeuroSense Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our NRSN earnings forecast.

When did NeuroSense Therapeutics IPO?: (NRSN) raised $13 million in an initial public offering (IPO) on Thursday, December 9th 2021. The company issued 2,000,000 shares at $6.00-$7.00 per share.
Who are NeuroSense Therapeutics' major shareholders?: NeuroSense Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (6.05%).
How do I buy shares of NeuroSense Therapeutics?: Shares of NRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NRSN) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial